24 Biotechnology Stocks to Sell Now

24 Biotechnology Stocks to Sell Now

This week, the ratings of 24 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Ligand Pharmaceuticals Incorporated (LGND) experiences a ratings drop this week, going from last week’s C to a D. Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of LGND stock.

Slipping from a C to a D rating, Incyte Corporation (INCY) takes a hit this week. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This week, Kite Pharma, Inc.’s (KITE) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of KITE stock.

DBV Technologies SA Sponsored ADR (DBVT) declines this week from a C to a D. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of DBVT stock.

Loxo Oncology Inc (LOXO) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

Portola Pharmaceuticals, Inc. (PTLA) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTLA stock.

This is a rough week for Atara Biotherapeutics Inc (ATRA). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATRA stock.

This week, Global Blood Therapeutics Inc (GBT) drops from a D to a F rating. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GBT stock.

CytomX Therapeutics, Inc.’s (CTMX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

OPKO Health, Inc. (OPK) earns a D this week, moving down from last week’s grade of C. OPKO Health, Inc. is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of OPK stock.

Advaxis, Inc. (ADXS) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

Lion Biotechnologies, Inc. (LBIO) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

GlycoMimetics, Inc. (GLYC) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

This week, Vascular Biogenics Ltd. (VBLT) drops from a C to a D rating. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VBLT stock.

Arrowhead Pharmaceuticals, Inc.’s (ARWR) rating weakens this week, dropping to a D versus last week’s C. Arrowhead Pharmaceuticals, Inc. a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARWR stock.

DelMar Pharmaceuticals, Inc. (DMPI) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of DMPI stock.

This is a rough week for VistaGen Therapeutics, Inc. (VTGN). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTGN stock.

Trovagene, Inc. (TROV) declines this week from a C to a D. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TROV stock.

CareDx, Inc. (CDNA) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

Ohr Pharmaceutical, Inc. (OHRP) slips from a C to a D this week. Ohr Pharmaceutical, Inc. develops pharmaceuticals for wound care and to treat cachexia. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

This week, Geron Corporation’s (GERN) rating worsens to a F from the company’s D rating a week ago. Geron Corporation is a biopharmaceutical company that discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. The company also gets F’s in sales growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of GERN stock.

Slipping from a C to a D rating, CorMedix Inc. (CRMD) takes a hit this week. CorMedix Inc. is a development-stage pharmaceutical company that seeks to fulfill selected, significant unmet medical needs in the therapeutic areas at the crossroads of cardiac and kidney (renal) disease. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRMD stock.

This week, OncoSec Medical Incorporated’s (ONCS) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONCS stock.

Verastem, Inc. (VSTM) is having a tough week. The company’s rating falls from a D to a F. Verastem, Inc. is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/24-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC